The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Chesnokova N.B.

FGBU Moskovskiĭ nauchno-issledovatel'skiĭ institut glaznykh bolezneĭ im. Gel'mgol'tsa Minzdrava RF, Moskva

Pavlenko T.A.

Moscow Helmholtz Research Institute of Eye Diseases, Moscow, Russia

Ugriumov M.V.

Institut biologii razvitiia im. N.K. Kol'tsova RAN, Moskva

Ophthalmic disorders as a manifestation of Parkinson's disease

Authors:

Chesnokova N.B., Pavlenko T.A., Ugriumov M.V.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(9): 124‑131

DOI: 10.17116/jnevro201711791124-131

Read: 10727 times

Contact the author
Table of contents

OPHTHALMIC DISORDERS AS A MANIFESTATION OF PARKINSON'S DISEASE
OPHTHALMIC DISORDERS AS A MANIFESTATION OF PARKINSON'S DISEASE

To cite this article:

Chesnokova NB, Pavlenko TA, Ugriumov MV. Ophthalmic disorders as a manifestation of Parkinson's disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2017;117(9):124‑131. (In Russ.)
https://doi.org/10.17116/jnevro201711791124-131

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Sleep diso­rders in patients with Lewy body deme­ntia and Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(4-2):81-87
Effect of uric acid on the progression of Parkinson’s disease: Myth or reality?. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7):7-14
Change of speech diso­rders during bila­teral deep stimulation of the subthalamic nucleus of the brain in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8):59-65
Oxidative stress and depression in Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(9):131-138
Current aspe­cts of the rela­tionship between depression and cognitive impairment in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(10):66-74
Musculoskeletal diso­rders in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(11-2):6-10
Sele­ction of patients with Parkinson’s disease for inte­rventional therapies: A review of available tools — scales and questionnaires. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(11-2):11-17
«Brain—gut—microbiome» axis in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(11-2):18-23
Pote­ntial and prospects of the astragaloside IV use for age-associated diseases prevention. Russian Journal of Preventive Medi­cine. 2025;(7):94-99
Dyna­mics of permeability of the blood-brain barrier after FUS thalamotomy acco­rding to contrast-enhanced MRI. Burdenko's Journal of Neurosurgery. 2025;(4):51-60
Abstract:

Parkinson's disease is a severe neurodegenerative disease accompanied with the degeneration of dopaminergic neurons in the central and peripheral nervous system. The diagnosis of Parkinson's disease can still be made only on the stage of irreversible and nearly total degeneration of the nigrostriatum dopaminergic system and exhaustion of brain compensatory mechanisms that explains the low efficacy of therapy. Ophthalmic pathology is one of the nonmotor symptoms of Parkinson's disease. This can be explained firstly by the fact that eye is a «peripheral part of brain» and secondly by the involvement of dopaminergic neurons (dopamine-producing cells) that are subject to the selective degeneration during Parkinson's disease in the regulation of visual function in the eye and brain. Dopaminergic neurons and dopamine receptors are present in all structures of the eye. Parkinson's disease cause abnormalities not only in the retina but in the whole optic tract and can be considered as peripheral manifestations of the disease that precede the well-known motor dysfunctions. This review describes ophthalmological symptoms of Parkinson's disease, possible pathophysiological mechanisms of their development, optical disorders in experimental models of Parkinson's disease and also the perspectives of experimental and clinical studies of visual disorders for the development of preclinical diagnosis of Parkinson’s disease.

Keywords:

Parkinson's disease
dopamine
degeneration dopamine-producing cells
ophthalmic pathology

Authors:

Chesnokova N.B.

FGBU Moskovskiĭ nauchno-issledovatel'skiĭ institut glaznykh bolezneĭ im. Gel'mgol'tsa Minzdrava RF, Moskva

Pavlenko T.A.

Moscow Helmholtz Research Institute of Eye Diseases, Moscow, Russia

Ugriumov M.V.

Institut biologii razvitiia im. N.K. Kol'tsova RAN, Moskva

Close metadata

References:

  1. Goldstein DS, Holmes C, Li ST, Bruce S, Metman LV, Cannon RO. Cardiac sympathetic denervation in Parkinson disease. Ann Intern Med. 2000;133(5):338-347. https://doi.org/10.7326/0003-4819-133-5-200009050-00009
  2. Perkin GD. Autonomic Function. In: F.C. Rose, R. Capildeo (eds.). Research Progress in Parkinson’s disease. Kent: Pitman Medical. 1981;111-125. https://doi.org/10.1017/S003329170004931X
  3. Braak H, Bohl JR, Muller CM, Rub U, de Vos RA, Del Tredici K. The staging procedure for the inclusion body pathology associated with sporadic Parkinson’s disease reconsidered. Mov Disord. 2006;21(12):2042-2051. https://doi.org/10.1002/mds.21065
  4. Ugrumov MV. Development of preclinical diagnostics and preventive treatment of neurodegenerative diseases. J neurology and psychiatry named after Korsakov. 2015;11:4-14. (In Russ.).
  5. Ugrumov MV. Neurodegenerative diseases: from genome to the whole organism. M.: Scientific world; 2014;1:28-33. (In Russ.).
  6. Haeggendal J, Malmfors T. Ebidence of dopamine-containing neurons in the retina of rabbits. Acta Physiol Scand. 1963;59:295-296. https://doi.org/10.1111/j.1748-1716.1963.tb02744.x
  7. Chesnokova NB, Grigor’ev AV, Pavlenko TA, Nikol’skaia II, Kost OA, Kazanskaia NF. The role of the components of the renin-angiotensin system in the ocular tissues in norm and pathology. Vestn Ross Akad Med Nauk. 2003;9:29-32. (In Russ.).
  8. Tamer C, Melek IM, Duman T, Oksuz H. Tear film tests in Parkinson’s disease patients. Ophtalmology. 2005;112(10):1795. https://doi.org/10.1016/j.ophtha.2005.04.025
  9. Martin XD, Brennan MC. Dopamine and its metabolites in human tears. Eur J Ophthalmol. 1993;3(2):83-88. https://doi.org/10.1007/s00216-013-6756-x
  10. Murakami T, Nakamura M, Fujihara T., Nakata K. Involvement of dopamine D1-like receptors in mediating increases in protein secretion from rabbit lacrimal gland. J Ocul Pharmacol Ther. 1999;15(5):447-454. https://doi.org/10.1089/jop.1999.15.447
  11. Comoglu SS, Guven H, Acar M, Ozturk G, Kopcer B. Tear levels of tumor necrosis factor-alpha in patients with Parkinson’s disease. Neurosci Lett. 2013;553:63-67. https://doi.org/10.1016/j.neulet.2013.08.019
  12. Zubareva TV, Kiseleva ZM. Catecholamine content of the lacrimal fluid of healthy people and glaucoma patients. Ophthalmologica. 1977;175(6):339-344. https://doi.org/10.1159/000308678
  13. Cavallotti C, Pescososolido N. Localization of dopamine receptors in the rabbit cornea. Cornea. 1999;18(6):721-728. https://doi.org/10.1097/00003226-199911000-00016
  14. Aksoy D, Ortak H, Kurt S, Cevik E, Cevik B. Central corneal thickness and its relationship to’s disease severity. Can J Ophthalmol. 2014;49(2):152-156. https://doi.org/10.1016/j.jcjo.2013.12.010
  15. Hiromatsu S, Araie M, Fujimori K. Endogenous catecholamine concentrations in rat iris-ciliary body. JPN J Ophthalmol. 1994;38(2):123-128. https://doi.org/10.1016/b978-0-7506-4063-3.50021-5
  16. Korczyn AD, Keren O. The effect of L-dopa on papillary diameter in mice. Experientia. 1982;38(4):481-482. https://doi.org/10.1007/bf01952650
  17. Giza E, Fotiou D, Bostantjopoulou S, Katsarou Z, Gerasimov G, Gotzamani-Psarrakou A, Karlovasitou A. Pupillometry and 123I-DaTSCAN imaging in Parkinson’s disease: a comparison study. Int J Neurosci. 2012;122(1):26-34. https://doi.org/10.3109/00207454.2011.619285
  18. Stergiou V, Fotiou D, Tsiptsios D. Pupillometric findings in patients with Parkinson’s disease and cognitive disorder. Int J Psychophysiol. 2009;72(2):97-101. https://doi.org/10.1016/j.ijpsycho.2008.10.010
  19. Hori N, Takamori M, Hirayama M, Watanabe H, Nakamura T, Yamashita F, Ito H, Sobue G. Pupillometry supersensitivity and visual disturbance in Parkinson’s disease. Clin Auton Res. 2008;18(1):20-27. https://doi.org/10.1007/s10286-008-0453-4
  20. Giza E, Fotiou D, Bostantjopoulou S, Katsarou Z, Karlovasitou A. Pupil light reflex in Parkinson’s disease: evaluation with pupillometry. Int J Neurosci. 2011;121(1):37-43. https://doi.org/10.3109/00207454.2010.526730
  21. Wensing G, Haase C, Brendel E, Bottcher MF. Pupillography as a sensitive, noninvasive biomarker in healthy volunteers: fist-in-man study of BAY 63-9044, a new 5-HT1A-receptor agonist withdopamine agonistic properties. Eur J Clin Pharmacol. 2007;63(12):1123-1128. https://doi.org/10.1007/s00228-007-0372-7
  22. Yeung L, Hang PT, Lin LL, Yang CH, Chiou GC. Effects of dopamine Antagonists in humane eye accommodation. J Ocul Pharmacol Ther. 2001;17(1):11-17. https://doi.org/10.1089/108076801750125595
  23. Trope GE, Sole M, Aedy L. Madapallimattam A. Levels of norepinephrine, epinephrine, dopamine, serotonin and N-acetylserotonin in aqueous humour. Can J Ophthalmol. 1987;22(3):152-154. https://doi.org/10.1016/0006-2952(61)90084-3
  24. Potter DE. Do dopamine and dopamine receptors have roles in modulating function in the anterior segment? The evidence. Progress in Retinal and Eye Research. 1996;15(1):103-111. https://doi.org/10.1016/1350-9462(95)00005-4
  25. Lograno MD, Daniele E, Govoni S. Biochemical and functional evidence for the presence of dopamine D1 receptors in the bovine ciliary body. Experimental Eye Research. 1990;51(5):495-501. https://doi.org/10.1016/0014-4835(90)90079-a
  26. Green K, Hensley A, Lollis G. Dopamine stimulation of passive permeability and secretion in the isolated rabbit ciliary epithelium. Experimental Eye Research. 1979;29(4):423-427. https://doi.org/10.1016/0014-4835(79)90059-9
  27. Pescosolido N, Parisi F, Russo P, Buomprisco G, Nebbioso M. Role of dopaminergic receptors in glaucomatous disease modulation. Bio Med Research International. 2013;1-5. https://doi.org/10.1155/2013/193048
  28. Virno M, Sampaolesi R, PecoriGiraldi J, De Gregorio F, Taloni M, Brusini P, Di Staso, Stecchi G. Ibopamine: D1-dopaminergic agonist in the diagnosis of glaucoma. J Glaucoma. 2013;22(1):5-9. https://doi.org/10.1097/IJG.0b013e3182311db4
  29. Nowacka B, Lubinski W, Honczarenko K, Potemkowski A, Safranow K. Ophthalmological features of Parkinson disease. Med Sci Monit. 2014;11:20:2243-2249. https://doi.org/10.12659/MSM.890861
  30. Reitsamer HA, Bogner B, Tockner B, Kiel JW. Effects of dorzolamide on choroidal blood flow, ciliary blood flow, and aqueous production in rabbits. Invest Ophthalmol Vis Sci. 2009;31:50(5):2301-2307. https://doi.org/10.1167/iovs.08-2468
  31. Huemer K, Zawinka C, Garhofer G, Golestani E, Litschauer B, Dorner G, Schmetterer L. Effects of dopamine on retinal and choroidal blood flow parameters in humans. Br J Ophthalmol. 2007;91:1194-1198. https://doi.org/10.1136/bjo.2006.113399
  32. Nakahara T, Mori A, Kurauchi Y, Sakamoto K, Ishii K. Neurovascular interactions in the retina: physiological and pathological roles. J Pharmacol Sci. 2013;123(2):79-84. https://doi.org/10.1254/jphs.13r03cp
  33. Kolb H, Nelson R. Off-alpha and off-beta ganglion cells in the cat retina. II. Neural circuitry as revealed by electron microscopy of HRP stains. J Comp Neurol. 1993;329:85-110. https://doi.org/10.1002/cne.903290107
  34. Firsov ML, Astakhova LA. The Role of Dopamine in Controlling Retinal Photoreceptor Function in Vertebrates. J Neuroscience and Behavioral Physiology. 2015;46(2):138-145. https://doi.org/10.1007/s11055-015-0210-9
  35. Xin D, Bloomfield SA. Comparison of the responses of AII amacrine cells in the dark- and light-adapted rabbit retina. Vis Neurosci. 1999;16:653-665. https://doi.org/10.1017/s0952523899164058
  36. Boycott ВВ, Wassle H. The morphological types of ganglion cells of the domestic cats retina. J Physiol. 1974;240:397. https://doi.org/10.1113/jphysiol.1974.sp010616
  37. Hedden WJ, Dowling JE. Theinterplexiform cell system. II. Effects of dopamine on goldfish retinal neurons. Proc R Soc Lond B Biol Sci. 1978;13:201(1142):27-55. https://doi.org/10.1098/rspb.1978.0031
  38. Veruki ML, Wassle H. localization of dopamine D1 receptors in rat retina. Eur J Neurosci. 1996;8:2286-2297. https://doi.org/10.1111/j.1460-9568.1996.tb01192.x
  39. Muresan Z, Besharse JC. D2-like dopamine receptors in amphibian retina: localization with fluorescent ligands. Journal of Comparative Neurology. 1993;331:149-160. https://doi.org/10.1002/cne.903310202
  40. Nguyen-Legros J, Simon A, Caille I, Bloch B. Immunocytochemical localization of dopamine D1 receptors in the retina of mammals. Visual Neuroscience. 1997;14:545-551. https://doi.org/10.1017/s0952523800012207
  41. Astakhova LA, Samoiliuk EV, Govardovskii VI, Firsov ML. cAMP controls rod photoreceptor sensitivity via multiple targets in the phototransduction cascade. J Gen Physiol. 2012;140(4):421-433. https://doi.org/10.1085/jgp.201210811
  42. Archibald NK, Clarke MP, Mosimann UP, Burn DJ. Visual symptoms in Parkinson’s disease and Parkinson’s disease dementia. Mov Disord. 2011;26(13):2387-2395. https://doi.org/10.1002/mds.23891
  43. Jones RD, Donaldson IM, Timmings PL. Impairment of high-contrast visual acuity in Parkinson’s disease. Mov Disord. 1992;7:232-238. https://doi.org/10.1002/mds.870070308
  44. Uc EY, Rizzo M, Anderson SW, Qian S, Rodnitzky RL, Dawson JD. Visual dysfunction in Parkinson disease without dementia. Neurology. 2005;65:1907-1913. https://doi.org/10.1212/01.wnl.0000191565.11065.11
  45. Nowacka B, Lubiсski W, Karczewicz D. Ophthalmological and electrophysiological features of Parkinson’s disease. Klin Oczna. 2010;112(7-9):247-252. https://doi.org/10.1093/med/9780199564118.003.011
  46. Garcia-Martin E, Satue M, Fuertes I, Otin S, Alarcia R, Herrero R, Bambo MP, Fernandez J, Pablo LE. Ability and reproducibility of Fourier-domain optical coherence tomography to detect retinal nerve fiber layer atrophy in Parkinson’s disease. Ophthalmology. 2012;119(10):2161-2157. https://doi.org/10.1016/j.ophtha.2012.05.003
  47. Garcia-Martin E, Larrosa JM, Polo V, Satue M, Marques ML, Alarcia R, Seral M, Fuertes I, Otin S, Pablo LE. Distribution of retinal layer atrophy in patients with Parkinson disease and association with disease severity and duration. Am J Ophthalmol. 2014;157(2):470-478. https://doi.org/10.1016/j.ajo.2013.09.028
  48. Tsironi EE, Dastiridou A, Katsanos A, Dardiotis E, Veliki S, Patramani G, Zacharaki F, Ralli S, Hadjigeorgiou GM. Perimetric and retinal nerve fiber layer findings in patients with Parkinson’s disease. BMC Ophthalmol. 2012;2:12:54. https://doi.org/10.1186/1471-2415-12-54
  49. Bayer AU, Ferrari F, Erb C. High occurrence rate of glaucoma among patients with Alzheimer’s disease. Eur Neurol. 2002;47(3):165-168. https://doi.org/10.1159/000047976
  50. Armstrong RA. Visual symptoms in Parkinson’s disease. Parkinsons Dis. 2011;9. https://doi.org/10.4061/2011/908306
  51. Castelo-Branco M, Mendes M, Silva F, Massano J, Januário G, Januário C, Freire A. Motion integration deficits are independent of magnocellular impairment in Parkinson’s disease. Neuropsychologia. 2009;47(2):314-320. https://doi.org/10.1016/j.neuropsychologia.2008.09.003
  52. Aung MH, Park H, Han MK, Obertone TS, Jane A, Asee F, Thule EM, Iuvon MP, Pardue MT. Dopamine Deficiency Contributes to Early Visual Dysfunction in a Rodent Model of Type 1 Diabetes. The Journal of Neuroscience. 2014;34(3):726-736. https://doi.org/10.1523/jneurosci.3483-13.2014
  53. Ugrumov MV. Neurodegenerative diseases: from genome to the whole organism. M.: Scientific world; 2014. (In Russ.).
  54. Ugrumov MV, Khaindrava VG. Modeling of presymptomatic and symptomatic stages of parkinsonism in mice. Neuroscience. 2011;181:175-188. https://doi.org/10.1016/j.neuroscience.2011.03.007
  55. Kozina EA, Khakimova GR, Khaindrava VG, Kucheryanu VG, Vorobyeva NE, Krasnov AN, Georgieva SG, Goff LK, Ugrumov MV. Tyrosine hydroxylase expression and activity in the nigrostriatal dopaminergic neurons of MPTP-treated mice at the presymptomatic and symptomatic stages of parkinsonism. J Neurological Sciences. 2014;340:198-207. https://doi.org/10.1016/j.jns.2014.03.028
  56. Hamilton WR, Trickler WJ, Robinson BL, Paule MG, Ali SF. Effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on retinal dopaminergic system in mice. Neuroscience letters. 2012;515:107-110. https://doi.org/10.1016/j.neulet.2012.02.085
  57. Muthane U, Ramsay KA, Jiang H, Jackson-Lewis V, Donaldson D, Fernando S, Ferreira M, Przedborski S. Differences in nigral neuron number and sensitivity to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in C57/bl and CD-1mice. Exp Neurol. 1994;126:195-204. https://doi.org/10.1006/exnr.1994.1058
  58. Takatsuna Y, Adachi-Usami E, Ino H, Chiba T. Effects of MPTP on the mouse retina. Nippon Ganka Gakkai Zasshi. 1992;96(6):767-775. https://doi.org/10.3109/02713689408999898
  59. Tatton WG, Kwan MM, Verrier MC, Seniuk NA, Theriault E. MPTP produces reversible disappearance of tyrosine hydroxylase-containing retinal amacrine Cells. Brain Res. 1990;10:527(1):21-31. https://doi.org/10.1016/0006-8993(90)91056-m
  60. Biehlmaier O, Alam M, Schmidt WJ. A rat model of Parkinsonism shows depletion of dopamine in the retina. Neurochem Int. 2007;50(1):189-195. https://doi.org/10.1016/j.neuint.2006.08.001
  61. Schmidt WJ, Alam M. Controversies on new animal models of Parkinson’s disease pro and con: the rotenone model of Parkinson’s disease (PD). J Neural Transm. 2006;70:273-276. https://doi.org/10.1007/978-3-211-45295-0_42
  62. Nagel F, Buhr M, Dietz GP. Tyrosine hydroxylase-positive amacrine interneurons in the mouse retina are resistant against the application of various parkinsonian toxins. Brain Res Bull. 2009;30:79(5):303-309. https://doi.org/10.1016/j.brainresbull.2009.04.010
  63. Naarendorp F, Hitchcock PF, Sieving PA. Dopaminergic modulation of rod pathway signals does not affect the scotopic ERG of cat at dark-adapted threshold. Journal of Neurophysiology. 1993;70:1681-1691.
  64. Willis GL, Moore C, Armstrong SM. Parkinson’sdisease lights and melanocytes: looking beyond the retina. Sci Rep. 2014;29:4:392. https://doi.org/10.1038/srep03921
  65. Stutz B, da Conceicao FS, Santos LE, Cadilhe DV, Fleming RL, Conceição FS, Luís ES, Daniel VC, Renata LF, Acquarone M, Gardino PF, Reis RM, Dickson PW, Dunkley PR, Rehen S, Houzel J, Mello FG. Murine dopaminergic Muller cells restore motor function in a model of Parkinson’s disease. J Neurochem. 2014;128(6):829-840. https://doi.org/10.1111/jnc.12475
  66. Ming M, Li X, Fan X, Yang D, Li L, Chen S, Gu Q, Le W. Retinal pigment epithelial cells secrete neurotrophic factors and synthesize dopamine: possible contribution to therapeutic effects of RPE cell transplantation in Parkinson’s disease. J Transl Med. 2009;7:53. https://doi.org/10.1186/1479-5876-7-53
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.